A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Public ClinicalTrials.gov record NCT04538664. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.
Study identification
- NCT ID
- NCT04538664
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 308 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2020 (Actual)
- Primary completion
- May 3, 2023 (Actual)
- Completion
- Aug 2, 2027 (Estimated)
- Last update posted
- Aug 31, 2026
2020 – 2027
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope 2 | Duarte | California | 91010 | — |
| University of California Irvine | Orange | California | 92868 | — |
| UCLA | Santa Monica | California | 90404 | — |
| Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| H. Lee Moffitt Cancer & Research Institute | Tampa | Florida | 33612 | — |
| University Cancer And Blood Center LLC | Athens | Georgia | 30607 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Washington University Medical Center | St Louis | Missouri | 63110 | — |
| Regional Cancer Care Associates LLC | East Brunswick | New Jersey | 08816 | — |
| Langone Health at NYC University, NYU School of Medicine | New York | New York | 10016 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Sanford Health | Sioux Falls | South Dakota | 57104 | — |
| Texas Oncology Pa | Tyler | Texas | 75702 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Blue Ridge Cancer Care | Salem | Virginia | 24153 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 215 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04538664, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04538664 live on ClinicalTrials.gov.